PHATHOM PHARMACEUTICALS, INC. (PHAT): Price and Financial Metrics
PHAT Price/Volume Stats
|Current price||$11.66||52-week high||$14.45|
|Prev. close||$11.63||52-week low||$5.84|
|Day high||$11.83||Avg. volume||435,230|
|50-day MA||$10.42||Dividend yield||N/A|
|200-day MA||$9.89||Market Cap||508.54M|
PHAT Stock Price Chart Interactive Chart >
PHATHOM PHARMACEUTICALS, INC. (PHAT) Company Bio
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
Most Popular Stories View All
PHAT Latest News Stream
|Loading, please wait...|
PHAT Latest Social Stream
View Full PHAT Social Stream
Latest PHAT News From Around the Web
Below are the latest news stories about PHATHOM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PHAT as an investment opportunity.
Phathom Pharmaceuticals Reports First Quarter 2023 Results
FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2023 and provided updates on recent regulatory progress. “This quarter, we made remarkable progress advancing mission-critical priorities that position Phathom to potentially deliver vonoprazan to patients suffering from Eros
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristicsMeta-analysis shows potassium-competitor acid blockers (PCABs), including vonoprazan, provide a longer duration of pH >4, higher predicted Erosive GERD healing rates, and lower probabilities of failure to achieve healing FLORHAM PARK, N.J., May 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: P
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences: 22nd Annual Needham Virtual Healthcare Conference, including a scheduled fireside chat on Tuesday, April 18, 2023 at 8:45 a.m. EDT. Management will also participate
Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection. Stock surges 8% following the news.
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarterCombined commercial launch of vonoprazan for erosive esophagitis and H. pylori indications expected Q4 2023, if approved FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroi
PHAT Price Returns
Loading social stream, please wait...